Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Biotechnology Company Biocon Ltd. announced that the Global Phase 3 study for its Recombinant Human Insulin (Insugen) conducted in Type 1 diabetes mellitus (T1DM) patients demonstrated comparable safety and efficacy with the innovator product.
This multi-center, randomized study was conducted in nearly 300 T1DM patients to compare efficacy, safety and immunogenicity of the company's Regular human insulin (Insugen R) and Isophane human insulin (Insugen N) against the innovator products (Actrapid and Insulatard) sourced from Europe.
http://www.rttnews.com/1994170/bioc...esults-for-its-recombinant-human-insulin.aspx
This multi-center, randomized study was conducted in nearly 300 T1DM patients to compare efficacy, safety and immunogenicity of the company's Regular human insulin (Insugen R) and Isophane human insulin (Insugen N) against the innovator products (Actrapid and Insulatard) sourced from Europe.
http://www.rttnews.com/1994170/bioc...esults-for-its-recombinant-human-insulin.aspx